TABLE 2.
Treatment | |||||||
---|---|---|---|---|---|---|---|
time | 0.02% CHX | 0.2% CHX | 2% CHX | 0.02% CHX+ Plasma | 0.2% CHX+ Plasma | 2% CHX+ Plasma | Plasma |
1 minute* | 39.67 ± 13.01 a | 5.67 ± 3.79 a,b | 0 a,b,c | 15.33 ± 11.59 a,c,d | 1 ± 1.73 a,b,d,e | 0 a,b,c | 36 ± 10 b,c,d,e |
2 minutes* | 28.67 ± 5.03 a | 5 ± 4.58 a,b | 0 a,b,c | 19 ± 6 a,b,c,d | 4.67 ± 4.73 a,d,e | 0 a,b,c | 30 ± 9.81 b,c,d,e |
3 minutes* | 27.33 ± 10.69 a | 4.67 ± 4.04 a,b | 0 a,c | 19.33 ± 6 b,c,d | 1.33 ± 2.31 a,d,e | 0 a,c | 10.33 ± 3.51 a,c,d,e |
5 minutes* | 23.67 ± 13.45 a | 3.67 ± 3.51 a,b | 0 a,c | 14.67 ± 9.29 b,c,d | 1.33 ± 1.53 a,d | 0 a,c | 5 ± 4.58 a,c |
The CFU values are described the survival rates that were compared with the negative control at 100%.
Denotes significant difference (p < 0.05) about the antifungal effect of CAMP for each trial time, the Kruscal–Wallis test.
a, b, c, d and eDenote significant difference (p < 0.05) about comparison of the antifungal effect of CAMP for each condition, the Mann‐Whitney U test.
Different letters mean statistically significant differences (p < 0.05).
Data are presented as mean standard deviation.